Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 932-935

  Jimenez Mejias M E ^a   Pachon J ^b   Becerril, B ^b   Palomino Nicas J ^b   Rodriguez Cobacho A ^b   Revuelta, M ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; SULBACTAM; SULTAMICILLIN; UREIDOPENICILLIN;

ACINETOBACTER; ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FEVER; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE;

EID: 0030978148     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.932     Document Type: Article

References (14)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
2. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology and predictors of mortality. Medicine (Baltimore) 1995;74:340-9.
3. Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-32.
4. Kollef MH, Silver P, Murphy DM, Trovilion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655-62.
5. Fagon J-Y, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
6. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993;17:843-9.
7. Jiménez-Mejias ME, López-Cortes L, Becerril B, Palomino J, del Nozal M, Pachón J. Acinetobacter meningitis. Risk factors and clinical features [abstract no 1182]. In: Abstracts of the 7th European Congress on Clinical Microbiology and Infectious Diseases (Vienna). Taufkirchen, Germany: European Society of Clinical Microbiology and Infectious Diseases, 1995.
8. Seifert H, Richter W, Pulverer G. Clinical and bacteriological features of relapsing shunt-associated meningitis due to Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1995;14:130-4.
9. Nguyen MH, Harris SP, Muder RR, Pasculle AW. Antibiotic-resistant Acinetobacter meningitis in neurosurgical patients. Neurosurgery 1994;35:851-5.
10. Kelkar R, Gordon SM, Giri N, et al. Epidemic iatrogenic Acinetobacter spp. meningitis following administration of intrathecal methotrexate. J Hosp Infect 1989;14:233-43.
11. Sanchez JF, Sanz-Hospital J, Guerrero A, Martinez-Beltran J, Quereda C. Curación con imipenem-cilastatino de una meningitis por Acinetobacler calcoacelicus. Enf Infec Microbiol Clin 1991;9:512-3.
12. Rouveix E, Bure AM, Regnier B, et al. Experience with imipenem/cilastatin in the intensive care unit. J Antimicrob Chemother 1986;18(suppl E):153-60.
13. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
14. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-32.